查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
出血性疾病治療市場
市場調查報告書
商品編碼
1193837

出血性疾病治療市場

Bleeding Disorders Treatment
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

全球出血性疾病治療的市場規模由於COVID-19後商務形勢的變化，在2022年估算為146億美金。該市場在2022年～2030年間預計將以5.2％的年複合成長率擴大，2030年之前達到220億美元。

本報告提供全球出血性疾病治療市場相關調查，提供市場概要，以及各地區趨勢，競爭策略等資訊。

調查對象企業範例(全46公司):

  • Bayer AG
  • CSL Behring
  • Grifols International SA
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer, Inc.

目錄

第1章 調查手法

第2章 摘要整理

  • 市場概要
  • 主要企業
  • 市場趨勢與推動因素
  • 全球市場預測

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲各國
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區各國
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家各國
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東各國
  • 非洲

第4章 競爭

簡介目錄
Product Code: MCP10745

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Bleeding Disorders Treatment Market to Reach $22 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Bleeding Disorders Treatment estimated at US$14.6 Billion in the year 2022, is projected to reach a revised size of US$22 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2022-2030. Hemophilia A, one of the segments analyzed in the report, is projected to record a 5.2% CAGR and reach US$12.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hemophilia B segment is readjusted to a revised 5.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4 Billion, While China is Forecast to Grow at 8.6% CAGR

The Bleeding Disorders Treatment market in the U.S. is estimated at US$4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.8% and 5.6% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.9% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$3 Billion by the year 2030.

Select Competitors (Total 46 Featured):

  • Bayer AG
  • CSL Behring
  • Grifols International SA
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Bleeding Disorders Treatment to Witness Steady Growth
    • Hemophilia A to Account for Highest Growth
    • Total Number of People Worldwide with Bleeding Disorders by Condition: 2017
    • Recombinant Coagulation Factor Concentrates to Register Largest Market Share
    • Total Recombinant Coagulation Factors Sales of Novo Nordisk
    • Bleeding Disorders Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
    • Bleeding Disorders Treatment Competitor Market Share Scenario Worldwide (in %): 2019 & 2025
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • A Prelude into Hemophilia Product Sales of Leading Players
    • Hemophilia Product Portfolio of Leading Players
    • Total Sales of Hemophilia Drugs by Leading Players-2017
    • Annual Hemophilia Product Sales of Shire in Billion USD for the years 2015, 2016, and 2017
    • Market Share of Novo Nordisk in Haemophilia: 2017
    • Total Sales for Novo Nordisk in Haemophilia Segment: 2018
    • Select Products in Developmental Stage
    • Select Mergers and Acquisitions
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Bleeding Disorders to Propel Market Prospects
    • Total Number of Patients with Bleeding Disorders for Select Countries: 1999 to 2017
    • Total Number Patients with Haemophilia A and Haemophilia B
    • Prophylactic Treatment in Hemophilia to Support Market Growth
    • Percentage Breakdown of Diagnosis and Treatment Rates in Haemophilia
    • Emerging Therapies/ Investments to Spur Market Demand
    • New Product Launches/ Approvals to Support Market Growth
    • Higher Cost of Drugs to Hinder Bleeding Disorders Treatment
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Bleeding Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Hemophilia A by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Hemophilia A by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hemophilia B by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hemophilia B by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Plasma-derived Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Plasma-derived Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Plasma-derived Coagulation Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Recombinant Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Recombinant Coagulation Factor Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Recombinant Coagulation Factor Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Fibrin Sealants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Fibrin Sealants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Fibrin Sealants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
    • TABLE 25: World Bleeding Disorders Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • CANADA
    • Percentage Breakdown of Total Population in Canada with Hemophilia by Age Group: 2017
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • JAPAN
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • CHINA
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: China 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: China 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • EUROPE
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Bleeding Disorders Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • FRANCE
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: France 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: France 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • GERMANY
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Bleeding Disorders Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • AUSTRALIA
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • INDIA
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 118: India 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 121: India 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • LATIN AMERICA
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Bleeding Disorders Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2023 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • MIDDLE EAST
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Bleeding Disorders Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Bleeding Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2023 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030
  • AFRICA
    • Bleeding Disorders Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Bleeding Disorders Treatment by Type - Hemophilia A, Hemophilia B and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Bleeding Disorders Treatment by Type - Percentage Breakdown of Value Sales for Hemophilia A, Hemophilia B and Other Types for the Years 2014, 2023 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Bleeding Disorders Treatment by Drug Class - Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Bleeding Disorders Treatment by Drug Class - Percentage Breakdown of Value Sales for Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Fibrin Sealants and Other Drug Classes for the Years 2014, 2023 & 2030

IV. COMPETITION